A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

NCT05867303 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma
Urothelial Carcinoma
Renal Cell Carcinoma
Non-small Cell Lung Cancer
Head and Neck Squamous Cell Carcinoma
Colorectal Carcinoma

Interventions

DRUG: RC198 Injection

Sponsor

RemeGen Co., Ltd.